Status:
COMPLETED
The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19.
Lead Sponsor:
D'Or Institute for Research and Education
Collaborating Sponsors:
Hospital Sao Rafael
Conditions:
Covid19
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
The COVID-19 pandemic is of grave concern due its impact on human health and on the economy. Propolis, a natural resin produced by bees from plant materials, has anti-inflammatory, immunomodulatory, a...
Eligibility Criteria
Inclusion
- Hospitalized patients;
- Positive RT-PCR for SARS-CoV-2;
- 18 Years and older.
Exclusion
- Pregnant women;
- People with active cancer;
- Patients undergoing transplantation of solid organs or bone marrow or who use immunosuppressive medications;
- HIV carriers;
- Allergy to propolis or any of its components;
- Bacterial infection at randomization;
- Sepsis or septic shock before randomization;
- Patients unable to use medication orally or via nasoenteral tube;
- Patients with severe chronic liver disease (Child B or C);
- Patients with advanced heart failure;
Key Trial Info
Start Date :
June 2 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 30 2020
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04480593
Start Date
June 2 2020
End Date
August 30 2020
Last Update
September 30 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Sao Rafael
Salvador, Estado de Bahia, Brazil, 41820340